Tripleitriumab
pMMR
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the pMMR cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Replimune, Inc. | Phase 2 | CCC |
Serplulimab First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Capecitabine First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Atezolizumab Replimune, Inc. | Phase 2 | CCC |
Dfn-15 Zhejiang University | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Tripleitriumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →